SCHEMBL5217217

SCHEMBL5217217

O=Cc1ccc(OCc2ccc(F)cc2F)c(OCc2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
POLB P06746 2/20 0.56
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
HPGD P15428 1/20 0.56
TACR2 P21452 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
MAOA P21397 3/20 0.46
MAOB P27338 3/20 0.46
GSK3B P49841 1/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
AKR1C3 P42330 2/20 0.45
SIRT2 Q8IXJ6 1/20 0.45
UBE2N P61088 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5215416 0.91 ALDH1A1 (0.65) ALDH1A1POLBKMT2AMEN1HPGD
SCHEMBL29446267 0.84 TACR2 (0.62) ALDH1A1POLBKMT2AMEN1HPGD
SCHEMBL584489 0.84 TACR2 (0.62) ALDH1A1POLBKMT2AMEN1HPGD
SCHEMBL14078205 0.84 ALDH1A1 (0.74) ALDH1A1POLBKMT2AMEN1HPGD
SCHEMBL5218024 0.81 AKR1C3 (0.56) ALDH1A1TACR2SMN1; SMN2MAPTMAOA
SCHEMBL5218194 0.81 TACR2 (0.63) ALDH1A1POLBKMT2AMEN1HPGD
SCHEMBL30628479 0.81 TACR2 (0.63) ALDH1A1POLBKMT2AMEN1HPGD
SCHEMBL5217272 0.81 TACR2 (0.57) ALDH1A1POLBKMT2AMEN1TACR2
SCHEMBL5216251 0.81 TACR2 (0.57) ALDH1A1POLBKMT2AMEN1TACR2
SCHEMBL31019272 0.80 ALDH1A1 (0.57) ALDH1A1POLBKMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313471-B1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS UCB SA (BE) 2007-04-11 EP disclosed
US-7105554-B2 Benzylidene thiazolidinediones and their use as antimycotic agents OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2006-09-12 US disclosed
US-20040006112-A1 Benzylidene thiazolidinediones and their use as antimycotic agents OXFORD GLYCOSCIENCES (UK) LTD (GB) 2004-01-08 US disclosed
EP-1313471-A1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS Oxford GlycoSciences (UK) Limited (GB) 2003-05-28 EP disclosed
WO-2002017915-A1 BENZYLIDENE THIAZOLIDINEDIONES AND THEIR USE AS ANTIMYCOTIC AGENTS OXFORD GLYCOSCIENCES (UK) LIMITED (GB) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006112-A1 Benzylidene thiazolidinediones and their use as antimycotic agents SLC5A2, OXSR1, SLC5A1 ALDH1A1 2757/4885POLB 3880/4885KMT2A 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.